secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001104659-22-002514
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx preliminary Q4 rev $3.6-3.7M (+71-77% YoY); FY2021 rev $13.0-13.1M (+113-116% YoY); FY2022 guidance $20-23M
--------------------------------------------------------------------------------

- Preliminary Q4 2021 revenue $3.6-$3.7M, up 71-77% YoY vs $2.1M.
- Full year 2021 revenue $13.0-$13.1M, up 113-116% from $6.1M in 2020.
- U.S. heart failure revenue $8.4M, Europe $3.9M, U.S. legacy $0.7M for 2021.
- Active implanting centers grew to 46 as of Dec 31, 2021 from 38 as of Sep 30, 2021.
- FY2022 revenue guidance $20-$23M; Q1 2022 expected $3.6-$4.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922002514/0001104659-22-002514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465922002514/tm222384d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-002514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer